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ABSTRACT 
Background: Sialic acid-binding immunoglobulin-like lectin (Siglec)-8 is expressed on mast 
cells and eosinophils, but information about Siglec-8 expression and function in the lung is 
limited. A humanized antibody, AK002, targeting Siglec-8 is undergoing development for 
treatment of diseases associated with mast cell and eosinophil-driven inflammation. 
Objective: To characterize Siglec-8 expression in the airway in asthma and determine if 
antibodies that target Siglec-8 (S8mAbs) can decrease airway eosinophils in asthma or 
inhibit lung mast cell activation. 
Methods: Gene expression profiling and flow cytometry were used to characterize Siglec-8 
expression in sputum cells from stable asthma. An antibody-dependent cellular cytotoxicity 
(ADCC) assay was used to determine if an S8mAb can decrease eosinophils in sputum from 
asthma patients ex vivo.  A mast cell activation assay was used to determine if an S8mAb 
can inhibit mast cell activation in human lung tissue ex vivo.  
Results: Gene expression for Siglec-8 is increased in sputum cells in asthma and correlates 
with gene expression for eosinophils and mast cells. Gene expression for Siglec-8 is 
inversely and significantly correlated with measures of airflow obstruction in asthma patients. 
Siglec-8 is prominently expressed on the surface of eosinophils and mast cells in sputum. 
S8mAbs decrease eosinophils in sputum from patients with asthma and inhibit FceR1-
activated mast cells in lung tissues. 
Conclusions and clinical relevance: Siglec-8 is highly expressed on eosinophils and mast 
cells in asthmatic sputum and targeting Siglec-8 with an antibody is a plausible strategy to 





Siglec-8 is member of the sialic acid binding immunoglobulin-like lectin (Siglec) family of 
immune receptors, and it is expressed on blood and tissue eosinophils, mast cells and 
(weakly) on basophils [1, 2]. Cross-linking of Siglec-8 with a monoclonal antibody (mAb) on 
blood eosinophils can mediate apoptosis via a caspase dependent pathway [3, 4], and 
activation of eosinophils with pro-inflammatory cytokines such as IL-5 further sensitizes 
eosinophils to Siglec-8-mediated apoptosis [5, 6]. This has particular relevance to asthma as 
eosinophils may be predisposed to apoptosis with anti-Siglec-8 mAbs due to elevated levels 
of pro-inflammatory cytokines. Engagement of Siglec-8 on mast cells does not cause 
apoptosis but induces broad inhibition of these cells [7, 8].  
 
The specific expression of Siglec-8 on eosinophils and mast cells has led to the 
development of AK002, a humanized, non-fucosylated IgG1 monoclonal antibody that 
targets Siglec-8 for therapeutic purposes in eosinophilic and mast cell-driven diseases [9].  
AK002 was developed with the idea that binding to Siglec-8 on eosinophils and mast cells 
would trigger antibody-dependent cellular cytotoxicity (ADCC) against blood eosinophils in 
the presence of NK cells, induce apoptosis of tissue eosinophils, and inhibit mast cells. 
Indeed, AK002 effectively depleted blood eosinophils in a phase I clinical trial and has 
demonstrated clinical activity in multiple mast cell and eosinophil-driven diseases 9,[10]. 
Recent studies have shown that bronchoalveolar lavage (BAL) eosinophils collected after 
airway allergen challenge in patients with mild asthma have high Siglec-8 expression [11] 
and that Siglec-8 is expressed on eosinophils and mast cells from dissociated lung tissue 
[8].  Other studies of eosinophils, performed in limited numbers of human lung tissue 
samples or in mice show that eosinophils can be depleted by an anti-Siglec-8 mAb [8, 12].   
 
To further understand the role of Siglec-8 in asthma and the utility of targeting eosinophils 
and mast cells with an anti-Siglec-8 mAb in the human airway, we set out here to 
characterize Siglec-8 gene expression in sputum cells from a large cohort of asthma patients 
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and healthy controls. We also explored whether an anti-Siglec-8 mAb can deplete 






























Induced sputum was collected from 74 asthmatic subjects and 37 healthy subjects (Table 1).  
The diagnosis of chronic stable asthma was defined as a prior physician diagnosis of 
asthma, and airway hyperreponsiveness (defined as a PC20 methacholine of less than 
8.0mg/ml while not taking steroids or less than 16mg/ml while taking steroids) or reversible 
airflow obstruction (postbronchodilator increase in FEV1 of ≥12%) in subjects whose FEV1 
percent predicted was less that 60%. For studies of sputum cell gene expression, RNA from 
induced sputum cells was available in the UCSF Airway Tissue Bank (ATB), a UCSF 
repository of biospecimens from patients with airway disease. The ATB uses common 
characterization procedures so that biospecimens are banked from subjects with  
standardized characterization data. For FACS-based studies which required freshly 
collected induced sputum, we designed a specific study protocol with an initial study visit for 
characterization purposes and additional study visits for sputum induction and collection of 
induced sputum for FACS and antibody depletion experiments. Venous blood was collected 
in parallel with induced sputum to allow for blood cell controls for the sputum cell 
experiments.  The ATB procedures and study protocol were reviewed and approved by the 
UCSF Institutional Review Board.  Fresh human lung tissue was procured and provided by 
the NCI Cooperative Human Tissue Network (CHTN) from subjects with no previous history 
of chronic lung disease, as approved by the Vanderbilt University Institutional Review Board 
(IRB# 031078 and 010294). 
 
Sputum collection 
Induced sputum was collected and processed according to previously published protocols 
[13]. Briefly, the subjects inhale a nebulized 3% solution of hypertonic saline through a 
mouthpiece for 12 minutes, pausing every two minutes to spit saliva into a saliva cup and 
sputum into a sputum cup. Saliva was discarded and sputum was processed using a 
standard protocol. Induced sputum was mixed in a 1:1 g/mL ratio with 10% sputolysin 
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(MilliporeSigma, Burlington, MA) and incubated at 37oC in a shaking water bath for 15 
minutes. At 5, 10 and 15 minute intervals, the sputum was mixed using a serological pipette. 
A 1mL aliquot of the mixture was used for cell counting and determination of cell 
differentials. Sputum with greater than 80% squamous cells were excluded from our studies 
as poor quality samples.  
 
RNA extraction and qPCR 
Dissociated sputum was centrifuged at 800g for 10 minutes at 4oC. The sputum cell pellet 
was resuspended in 1mL of Saliva Protect reagent (Qiagen, Germantown, MD) and stored 
at -80oC until RNA extraction. Induced sputum was collected from a further six subjects for 
each of flow cytometry staining and ADCC mediated killing assays (Table 1).  The sputum 
was processed as described below in the respective sections. Sputum RNA was extracted 
using RNeasy kits (Qiagen, Germantown, MD) according to our previously published 
protocols [14]. RNA was assessed for quality using an Agilent Bioanalyzer (Santa Clara, CA) 
that assigns a metric called the RNA Integrity Number (RIN) where 1 is poor quality and 10 
is excellent. RNA with a RIN of less than 5 were excluded from the study.  Taqman gene 
expression profiling on sputum cell RNA was performed according to our previous protocols 
[14]. All gene expression data were in the linear portion of the amplification curve. Samples 
that could not generate signal after 40 cycles were assigned a value equal to the minimum 
expression for that gene in other samples for analysis.  Gene expression data was 
compared and normalized against the geometric mean of four housekeeping genes 
(GAPDH, YWHAZ, PSMB2 and PPIA). Primer and probe details are shown in Table S1.  
 
Eosinophil peroxidase ELISA 
For quantification of eosinophil peroxidase, induced sputum supernatant was assayed 
using a Human EPO ELISA kit (Diagnostics Development, Sweden).  Samples were 
incubated in wells coated with anti-human EPO mouse monoclonal antibodies. After 
washing, a biotinylated anti-human EPO mouse monoclonal antibody was added to the wells 
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and incubated for 60 minutes at room temperature. After further washing, streptavidin 
conjugated with horseradish peroxidase (HRP) was added to the wells and incubated for 30 
minutes at room temperature. More washes were performed, then the HRP substrate, TMB 
(3,3′,5,5′-Tetramethylbenzidine), was added to the wells and allowed to incubate for 15 
minutes. A sulfuric acid solution (2 N H2SO3) was added to each well to terminate the 
enzyme reaction and to stabilize the color development. The optical density of each well was 
measured at 450nm using a microplate reader. The concentration of EPO was calculated 
from the dose response standard curve, using a 4 parameter logistic curve fit. 
 
Anti-Siglec-8 monoclonal antibodies 
The S8mAb used in these studies refers to a non-fucosylated chimeric 2E2 IgG1 (c2E2 IgG1 
KIF) mAb comprised of murine variable regions specific for Siglec-8 attached to non-
fucosylated human κ and IgG1 constant regions, as previously described [15]. Pre–clinical-
grade fully human IgG1 antibodies were used as an isotype control (Eureka Therapeutics, 
Emeryville, Calif). 
 
Flow cytometry staining  
Dissociated sample was passed through a 70µm cell strainer prior to cell counting. The 
sample was centrifuged at 800g for 10 minutes at 4oC. The supernatant was discarded and 
the cells were resuspended in PBS + 0.1% BSA + 2mM EDTA. Sputum samples were 
treated with Fc Block at 1:100 (BD Biosciences, San Jose, CA) for five minutes before being 
stained with a cocktail of antibodies (Table S2) for 30 minutes on ice. FMO controls 
contained the antibody panel with the exception of anti-Siglec-8. Cells were washed twice in 
PBS + 0.1% BSA + 2mM EDTA and if secondary reagents were required, they were added 
for 30 minutes at 4oC.  Cells were washed twice in PBS + 0.1% BSA + 2mM EDTA prior to 
analysis on a Becton Dickenson LSRII. Dextran gradient purified leukocytes were used as 
compensation controls, and the cells were stained as described above using the antibody 
panel shown in Table S3. For human lung tissue, approximately 0.1–0.5x106 cells/well were 
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incubated in 96-well plates with Human Fc Block (BD Biosciences, San Jose, CA) for 10 
minutes at 4°C followed by staining with conjugated antibodies for 10 minutes at 4°C. Cells 
were then washed with FACS buffer (0.1% bovine serum albumin [BSA] in PBS), 
resuspended in fixative (1% paraformaldehyde in PBS) and analyzed on a NovoCyte flow 
cytometer (Acea Biosciences, San Diego, CA). Mast cell were identified in lung tissue as 
CD45+ 7AAD- CD117+ FceRI+. 
 
Peripheral blood leukocyte processing 
20 mL of blood was collected by venipuncture into EDTA containing vacutainers (BD 
Biosciences, San Jose, CA). The blood was diluted  2:1 with PBS and mixed with a 3% 
solution of dextran (500,000MW, Alfa Aesar, Tewksbury, MA) before being allowed to 
sediment at 37oC. The white cells were removed in the top layer and the bottom layer 
containing red blood cells was discarded. Cells were washed with PBS + 0.1% BSA + 2mM 
EDTA prior to use. Cells were stored in liquid nitrogen in RPMI + 40% FBS + 10% DMSO. 
 
Blood eosinophil killing assays  
Human blood eosinophil apoptosis and ADCC was measured as previously described [8, 
15]. Briefly human eosinophils were purified and then seeded in 96-well flat-bottom tissue 
culture plates at 20,000 eosinophils/well. S8mAb or isotype control antibody (Allakos, Inc.) 
were added at 10 μg/mL in the presence of 50 ng/mL IL-3 or overnight activated human NK 
cells (effector : target 10:1 ratio). Cells were cultured overnight at 37°C in 5% CO2. 
Following overnight incubation, cells were stained with 7AAD and Annexin V-PE (BD 
Biosciences) for 30 min at room temperature in the dark. The labeled eosinophils were 
analyzed by flow cytometry, and percentage of dead eosinophils was determined.  
 
Sputum ADCC assay 
Dissociated sputum was centrifuged at 800g for 10 minutes at 4oC, and the cell pellet was 
resuspended in ADCC media (RPMI + 10% FCS + 1% P/S, 1% amphotericin B, 0.1% 
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gentamycin, 1% Nystatin and 1µM Econazole). Cells were passed through a 70µm cell 
strainer and plated into a 12 well cell culture plate. Purified NK cells that had been activated 
in culture overnight in RPMI + 10% FCS + 1% P/S + 5ng/µl rIL-2 were added to the wells at 
an effector:target ratio of 1:1 NK: sputum cell (assuming approximate ratio of 10:1 
effector:target NK: Siglec-8 bearing cell). Finally, S8mAb or isotype matched control 
antibody (Allakos, Redwood City, CA) were added to the wells at a final concentration of 
10µg /ml. Cells were cultured for 24 hours in the presence of antibodies. 50,000 cells were 
removed to make cytospin slides and determination of eosinophil %.    
 
Human lung tissue and mast cell activation assay 
Fresh human lung tissue was procured and provided by the NCI Cooperative Human Tissue 
Network (CHTN) from subjects with no previous history of chronic lung disease. The tissue 
was enzymatically and mechanically dissociated using the gentleMACs™ Dissociator 
(Miltenyi Biotec), according to manufacturer’s protocol. Tissue was minced into 2 mm pieces 
and incubated at 37°C for one hour in digestion solution containing proprietary enzymes. 
Before, during, and after incubation, tissue was mechanically disrupted and run through a 
70-micron filter to obtain single cells. Cells were then treated with RBC lysing buffer, washed 
in PBS and resuspended in RPMI 1640+10% Low IgG FBS. Immediately after digestion, cell 
viability was examined using flow cytometry. Only single-cell suspensions from dissociated 
tissue that had at least 70% viability were used in subsequent experiments. To activate mast 
cells, approximately 0.1-0.5 x 106 cells were plated/well in 96-well U-bottom plates with the 
indicated concentration of anti-FceRI (CRA-1, BioLegend, San Diego, CA) for 30 minutes at 
37°C followed by analysis of CD63 MFI on mast cells by flow cytometry. The mast cell 
inhibitory activity of anti-Siglec-8 was determined by incubating either 5 µg/mL S8mAb or 
isotype matched control antibody (Allakos, Inc) simultaneously with anti-FceRI for 30 
minutes at 37°C followed by flow cytometry analysis as described above. DCD63 MFI was 
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calculated by subtracting the unstimulated CD63 MFI from the MFI of CRA-1 stimulated 
cells.   
 
Statistical analysis 
Data analyses were performed GraphPad Prism version seven (GraphPad, San Diego, CA). 
ANOVA was used for three-group comparisons followed by pairwise analyses with the Tukey 
multiple comparisons test when appropriate. Two group comparisons were analyzed using the 




Siglec-8 gene expression in airway sputum cells.  
Siglec-8 has been shown to be expressed as a long form isoform with a cytoplasmic tail 
containing the typical Siglec tyrosine-based inhibitory motif (ITIM) and ITIM-like motif and a 
short form isoform that lacks the cytoplasmic tail [16].  Accordingly, we designed two 
different primer sets, one in the extracellular domain to measure all forms of Siglec-8 and 
one in the intracellular domain to measure the isoform with signaling motifs in the 
cytoplasmic tail (Fig 1A). We found similar patterns of gene expression for both primer sets 
in sputum cells from asthma subjects and healthy controls, suggesting that Siglec-8 long 
isoform expression is representative of overall Siglec-8 expression (Fig 1B). Based on these 
data, we focused subsequent analyses on data generated for the long Siglec-8 isoform 
containing the signaling motifs. We found that Siglec-8 gene expression in sputum cells from 
patients with asthma is significantly higher than in healthy controls (Fig 1B), including in a 
subset of asthma subjects taking inhaled corticosteroids (ICS) (Fig 1C). 
 
We next examined the relationship between Siglec-8 gene expression and sputum 
eosinophils. We found that the expression of Siglec-8 in sputum cells from asthma subjects 
strongly correlated with the sputum eosinophil percentage (Fig 2A) and eosinophil 
peroxidase (EPO) in sputum supernatants (Fig 2B). Siglec-8 was also strongly correlated 
with the expression of galectin-10 (an eosinophil related gene)(Fig 2C), tryptase and 
carboxypeptidase A3 (CPA3) (mast cell genes)(Fig 2D, 2E), and chemoattractant receptor–
homologous molecule expressed on receptor on TH2 cells (CRTH2) (Fig 2F), IL-4, IL-5 and 
IL-13 (genes related to type 2 inflammation)(Fig 2G-I). These data support that eosinophils 
and mast cells are the only cell sources of Siglec-8 expression in sputum from asthma 
subjects and that Siglec-8 gene expression correlates with features of type 2-high asthma. 
 
To determine how Siglec-8 gene expression in sputum cells relates to age and asthma 
severity, we examined relationships between Siglec-8 expression and age and measures of 
 12 
airflow.  We found that Siglec-8 expression increases significantly with age (Fig 2J) and is 
inversely correlated with FEV1 (Fig 2K).  
 
Siglec-8 expression on airway cells by flow cytometry.  
Building on our gene expression data, we set out to examine expression of Siglec-8 on 
eosinophils, mast cells and basophils in sputum.  Although immunostaining blood cells with 
anti-CCR3 works well to stain eosinophils, we found that immunostaining sputum cells with 
anti-CCR3 does not (data not shown). Eosinophils are lineage negative cells with high side 
scatter and high expression of CD45 [17], so we gated sputum cells on live/dead, size, and 
singlets in order to identify eosinophils as CD45hi and lineagelo. To verify that sputum cells 
within this gate were eosinophils, we validated the approach in peripheral blood cells. We 
found that blood eosinophils that were CD45hi/lineage lo showed high expression of both 
CCR3 and Siglec-8 (Fig 3A). Backgating analyses based on Siglec-8 positive cells showed 
that Siglec-8 expressing cells were localized in this gate (Fig 3B). Applying this gating 
strategy to sputum cells showed that airway eosinophils strongly express Siglec-8 (Fig 3C). 
Backgating Siglec-8 expressing cells in sputum showed these cells localize to the 
CD45hi/lineagelo gate (Fig 3D).  
 
To identify mast cell and basophils in sputum, we gated on a population of CD45hi, lineagelo 
cells and defined mast cells as c-kithi, FceR1hi and basophils as FceR1hi c-kit-. In agreement 
with previously published studies in blood cells [2] , we found that Siglec-8 was strongly 
expressed on airway mast cells (Fig 4A) while expression of Siglec-8 on airway basophils 
was very weak (Fig 4A) and similar to the weak expression seen on peripheral blood 
basophils (Fig 4B).  
 
ADCC mediated depletion of asthmatic sputum eosinophils.  
Previous studies have demonstrated that S8mAb treatment induces apoptosis of cytokine-
primed eosinophils and ADCC of blood eosinophils in the presence of NK cells  [15]. 
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Eosinophils are relatively rare in sputum therefore in order to explore if an anti-Siglec-8 
antibody could deplete eosinophils in sputum, we first tested if S8mAb-mediated apoptosis 
or ADCC was the more potent mechanism at reducing eosinophils ex vivo. Using healthy 
donor peripheral blood eosinophils, we found a much higher rate of eosinophil death in the 
presence of NK cells (Figure 5A) suggesting ADCC is the more potent mechanism of 
eosinophil reduction. Next we developed an ex vivo ADCC sputum cell assay using 
asthmatic subjects, summarized in Fig 5B. After 24 hours in culture, dead cells are removed 
using magnetic bead selection and the remaining cells are enumerated on cytospin slide 
preparations. In each of six sputum samples tested (independent donors), we found that the 
percentage of eosinophils in sputum treated with the S8mAb was significantly lower than 
when it was treated with the isotype control antibody (Fig 5C).   
 
Inhibition of IgE-mediated mast cell activation in human lung tissue 
Crosslinking of Siglec-8 with an antibody induces broad inhibition of mast cell activity in vitro 
and in vivo [7, 8, 12]. Since mast cells in sputum are rare, we isolated mast cells from fresh 
human lung tissue in order to test the activity of an anti-Siglec-8 antibody. Human lung mast 
cells were identified by as CD45hi, viable 7AADlo, c-kithi, FceR1hi (Supplemental Fig. S1) and 
robustly expressed Siglec-8 as previously published [12]. Human lung tissue mast cells were 
activated through the FceR1 by an anti-FceR1 antibody (CRA-1) which has been shown to 
induce mast cell degranulation in vitro [7]. To evaluate if human lung mast cells could be 
activated ex vivo, we titrated CRA-1 and analyzed the degranulation marker CD63 on lung 
mast cells. CRA-1 activated lung mast cells in a dose dependent manner, as evidenced by 
upregulation of CD63 (Fig. 6A). Next, we examined CRA-1 mediated mast cell activation in 
the presence of S8mAb or isotype control mAb (Fig. 6B). In each of the five human lung 
tissues tested (independent donors), S8mAb significantly decreased CRA-1 mediated CD63 
upregulation compared to isotype control antibody treated mast cells (Fig. 6C-E). The 
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reduction in CD63 expression was not associated with a decrease in mast cell number after 





























In this study we characterized the expression of Siglec-8 in induced sputum cells from 
patients with chronic stable asthma. We found that Siglec-8 gene expression correlates 
closely with airway gene expression for eosinophils, mast cells and type 2 cytokines and that 
the surface expression is high on eosinophils and mast cells. Using ex vivo assays in 
sputum and human lung tissue, we demonstrate for the first time, that an anti Siglec-8 
antibody can evoke ADCC activity to decrease asthmatic sputum eosinophils and inhibit IgE-
mediated mast cell activation in human lung tissue. 
 
In initial experiments, we examined Siglec-8 gene expression in sputum cells from patients 
with chronic stable asthma and a group of healthy control subjects. Siglec-8 gene 
expression was increased in asthma and this increase was evident even in patients who 
were being treated with inhaled corticosteroids.  We anticipated that Siglec-8 expression 
would be associated with biomarkers of eosinophils and mast cells in sputum and this 
proved correct.   
 
Siglec-8 correlated closely with eosinophil percentage and even more strongly with multiple 
gene expression markers of eosinophil and mast cells. Eosinophils and mast cells are key 
cells in type 2 immune responses, and we also found that Siglec-8 expression correlated 
very strongly with gene expression for prostaglandin D2 receptor 2 (DP2 or CRTH2) and 
type 2 cytokines.  Taken together, these gene expression data support that Siglec-8 gene 
expression in asthma sputum cells is a feature of the type 2-high subtype of asthma. Type 2-
high asthma is characterized by older age and more severe airflow obstruction than the type 
2-low endotype [18, 19] ; consistent with this, we report that Siglec-8 expression is 
associated with older age and with measures of airflow obstruction in asthma.  
 
Our flow cytometry data for Siglec-8 expression on airway eosinophils and mast cells from 
asthma sputum confirm and extend prior published data. Siglec-8 has been identified in 
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studies of peripheral blood eosinophils [1-3] and in BAL eosinophils after allergen challenge 
[11] but had not previously been investigated in chronic stable asthma.  Studies in mast cells 
are not as numerous, but experiments using cord blood [2] and dissociated tissues from 
human lung and skin [8] have consistently found that Siglec-8 is expressed on mast cells.  
Less consistent has been Siglec-8 expression on basophils and we show here that Siglec-8 
expression on basophils is weak both in the blood and sputum compartments.   
 
AK002 is a humanized non-fucosylated IgG1 antibody directed against Siglec-8 that has 
shown enhanced NK cell-mediated ADCC activity in against blood eosinophils and apoptosis 
of tissue eosinophils. Eosinophils from type 2-high asthmatics could have a higher sensitivity 
to treatment with AK002 due to priming with IL-5 which increases sensitivity to apoptosis [6]. 
The studies here were done using a non-fucosylated chimeric anti-Siglec-8 antibody that is 
an analog to AK002. We first tested whether treatment with a S8mAb could decrease 
sputum eosinophils.  We found that S8mAb treatment caused significant depletion of 
eosinophils in induced sputum from multiple donors when the sputum cells were cultured 
overnight in the presence of NK cells.  Thus, we have demonstrated that anti-Siglec-8 
antibodies can mediate ADCC activity against airway eosinophils raising the possibility that 
anti-Siglec-8 antibodies such as AK002 might have clinical utility in asthma.   
 
In contrast to the ADCC and apoptosis activity seen with eosinophils, Siglec-8 antibody 
crosslinking does not induce apoptosis or kill mast cells [7, 8]. Instead, Siglec-8 mAbs inhibit 
mast cell activation both in vitro [7] and in vivo, including in a humanized IgE-mediated 
systemic anaphylaxis model and an allergic eosinophilic gastroenteritis model [8, 12]. To our 
knowledge, S8mAb-mediated inhibition of mast cells has not been demonstrated in primary 
human lung mast cells. We found that S8mAb treatment inhibits activation and degranulation 
of human lung mast cells. The decrease in mast cell activation after S8mAb treatment was 
not associated with a reduction in mast cell number, consistent with the lack of killing seen 
after S8mAb crosslinking on mast cells.  
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In summary, we report that Siglec-8 is robustly expressed in sputum eosinophils and mast 
cells in asthma and is associated with type 2 immune profiles in these samples. Targeting 
Siglec-8 with an anti-Siglec-8 antibody, such as AK002 is a plausible strategy to decrease 
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Figure 1: Siglec-8 gene expression is increased in asthma sputum cells. A) Schematic 
showing location of extracellular and intracellular primer sets. B) Quantification of Siglec-8 
gene expression by qPCR showed that Siglec-8 is significantly upregulated in asthma 
sputum cells with both primer sets. C) Siglec-8 is significantly upregulated in sputum cells 
from asthmatic subjects taking ICS.  
 
Figure 2: Siglec-8 gene expression correlates with eosinophils, mast cells, and lung 
function.  A) Siglec-8 gene expression in asthma sputum cells is strongly correlated with 
sputum eosinophil percentage and B) EPO; C) Galectin-10; D-E) tryptase, CPA3; T2 related 
genes F-I) CRTH2, IL-4, IL-5 and IL-13 and J) age.  K) Siglec-8 gene expression in asthma 
sputum cells inversely correlates with FEV 1 (% predicted).  
 
Figure 3: Siglec-8 is expressed on the majority of sputum eosinophils. A) Gating 
strategy to identify eosinophils as CD45hi, lineagelo in sputum cells. B) Backgating of Siglec-
8 positive cells in peripheral blood. C) Airway eosinophils strongly express Siglec-8 
compared to FMO control. D) Backgating Siglec-8 positive cells in sputum to validate gating 
strategy. In each panel Siglec-8 is shown in the black outline with an FMO control in the grey 
outline. 
 
Figure 4. Siglec-8 is strongly expressed on sputum mast cells but very weakly on 
sputum basophils. A) Sputum mast cells express high levels of Siglec-8 in comparison to 
the very low but detectable levels of Siglec-8 on airway basophils. B) Peripheral blood 
basophils show a similar level of Siglec-8 staining as airway basophils. In each panel Siglec-
8 is shown in the black outline with an FMO control in the grey outline.  
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Figure 5: ADCC mediated depletion of eosinophils. A) Cytokine-primed eosinophils from 
peripheral blood show lower rates of cell death when treated with S8mAb alone (apoptosis) 
compared to ADCC in the presence of NK cells. B) Schematic showing experimental 
strategy to isolate cells from sputum and culture in the presence of activated NK cells and 
S8mab or control antibody. C) Treatment of sputum cells with S8mAb and NK cells results in 
a significant decrease in sputum eosinophils.  
 
Figure 6: Anti-Siglec-8 inhibits IgE-mediated human lung mast cell activation. A) The 
percentage of CD63+ mast cells after incubation with anti-FceRI antibody (CRA-1). B) 
Schematic showing ex vivo mast cell activation assay. C) Representative dot plots of the 
percentage of CD63+ mast cells D) The percentage of CD63+ mast cells or E) DCD63 MFI on 







































































































FACS study Depletion Study
Healthy Asthma Asthma Asthma
N 37 74 7 8
Age, yr 34 ± 11.2 40.4 ± 16 48.4 ± 16.9 49.3 ± 16.4
Female, n (%) 21 (56.8) 46 (62.2) 5 (71.4) 5 (62.5)
BMI, kg/m2 25.7 ± 6.6 29.8 ± 7.9 29.8 ± 5.6 30.1 ± 8.1
FEV1, (L) 3.3 ± 0.8 2.6 ± 1.0 2.3 ± 1.1 2.2 ± 0.9
FEV1, (% predicted) 80.5 ± 37.4 73 ± 25.4 70.5 ± 15.7 68.4 ± 16.4
PC20 mg/ml N/A     1.5 ± 1.9 1.0 ± 1.1 0.8 ± 0.9
On ICS, n (%) N/A 43 (58.1) 2 (33.3) 5 (71.4)
Peripheral blood eosinophils, (109/ L) 0.1 ± 0.1 0.3 ± 0.2 0.4 ± 0.2     0.9 ± 1.1
Smoking History
Never, n (%) 24 (64.9) 48 (65.8) 5 (71.4) 7 (87.5)
Former, n (%) 13 (35.1) 25 (34.2) 2 (28.6) 1 (12.5)
Pack-years 0.3 ± 0.9 0.6 ± 1.5 0.3 ± 0.8 0.0 ± 0.0
qPCR study 
Table I. Subject characteristics
Supplement Figure S1: Gating strategy for mast cells in human lung tissue. Human 
lung tissue was dissociated into single cells. Following dissociation, mast cells were stained 
for flow cytometry and gated as CD45+ 7AAD- C-kit+ FceRI+. Mast cells were stained with 




















Supplemental Table 1 
 
Primer Sequence 
Tryptase RTF GCCATTTCCTCTGAAGCAGGT 
Tryptase RTR GCATGTCGTCACGGACGAT 
Tryptase TMF GGTCCCCATAATGGAAAACCA 
Tryptase TMR GGACGTCGTCTCCCGTGTA 
Tryptase TMP TTGTGACGCAAAATACCACCTTGGCG 
CPA3 RTF AGGATGAAAAACAAGCAGACATCA 
CPA3 RTR CAGACTGGATGGCTTGGGATT 
CPA3 TMF CAAAACCAATGAGCTTGACTTCTG 
CPA3 TMR CGGAAATCCACCATCATATTAGC 
CPA3 TMP TCCAGGTGCCACCCACCACGTA 
CRTH2 RTF GGCACTCACACGCGAAAGTAT 
CRTH2 RTR TCAAGGTTTGAGAAGCACTGCTT 
CRTH2 TMF GGCACTCACACGCGAAAGTAT 
CRTH2 TMR GGCAGGAGTCCGGATATCG 
CRTH2 TMP TTGAACCGCGGCACCCTGGT 
Siglec-8 All RTF GAACTTGACCATGACTGTCTTCCA 
Siglec-8 All RTR GCTGTTGACAGCACAGACCAG 
Siglec-8 All TMF TCTTCCAAGGAGATGCCACA 
Siglec-8 All TMR GGCCCTCAAGGACTGAAAGA 
Siglec-8 All TMP CCACAGCCCTGGGAAATGGCTC 
Siglec-8L RTF CAACCCTCAGCTTCCATAAAGTG 
Siglec-8L RTR ATTCCTCAAACAGGCCTGAGTCT 
Siglec-8L TMF TCCATAAAGTGAAGCCTCAGGA 
Siglec-8L TMR GCAGTTTCTCGCTTGTGGAT 
Siglec-8L TMP CAGTGGCCTCCTGTCCCTGCG 
IL-4 RTF GGGTCTCACCTCCCAACTGC 
IL-4 RTR TGTCTGTTACGGTCAACTCGGT 
IL-4 TMF GCTTCCCCCTCTGTTCTTCCT 
IL-4 TMR GCTCTGTGAGGCTGTTCAAAGTT 
IL-4 TMP TCCACGGACACAAGTGCGATATCACC 
IL-5 RTF GCCATGAGGATGCTTCTGCA 
IL-5 RTR GAATCCTCAGAGTCTCATTGGCTATC 
IL-5 TMF AGCTGCCTACGTGTATGCCA 
IL-5 TMR GTGCCAAGGTCTCTTTCACCA 
IL-5 TMP CCCCACAGAAATTCCCACAAGTGCA 
IL-13 RTF CAACCTGACAGCTGGCATGT 
IL-13 RTR CCTTGTGCGGGCAGAATC 
IL-13 TMF GCCCTGGAATCCCTGATCA 
IL-13 TMR GCTCAGCATCCTCTGGGTCTT 
IL-13 TMP TCGATGGCACTGCAGCCTGACA 
ST2 RTF AAATTCTGGAAGCACGTGAGGTA 
ST2 RTR TCAGGAAAGCTTCAAACTCAGATG 
ST2 TMF TCCCAGAAAGGCCTCTAGTTTG 
ST2 TMR TCAGATGCCTTTGCACATCA 
ST2 TMP CAGCAGGCACTATTGCTTCTGGGCA 
Galectin-10 RTF GTCTTCCATTTCCAAGTGTGCTTT 
Galectin-10  RTR GTGTAAGAGGATTGGCCATTGAC 
Galectin-10  TMF CCTTTCAGGATGGCCAAGAA 
Galectin-10  TMR TGGCCATTGACCATTACCTG 
Galectin-10  TMP CTGGCAGCACTGAGATGCTCAGTTCA 
PPIA RTF  ATGAGAACTTCATCCTAAAGCATACG 
PPIA RTR TTGGCAGTGCAGATGAAAAACT 
PPIA TMF ACGGGTCCTGGCATCTTGT 
PPIA TMR GCAGATGAAAAACTGGGAACCA 
PPIA TMP ATGGCAAATGCTGGACCCAACACA 
PSMB2 RTF  CCATATCATGTGAACCTCCTCCT 
PSMB2 RTR GTCGAGGATACTGAGAGTCAGGAA 
PSMB2 TMF TCCTCCTGGCTGGCTATGAT 
PSMB2 TMR GGCTGCCAGGTAGTCCATGT 
PSMB2 TMP ACAGCGCTGGCCCTTCATGCTC 
YWHAZ RTF CTTCTGTCTTGTCACCAACCATTC 
YWHAZ  RTR CAACTAAGGAGAGATTTGCTGCAG 
YWHAZ  TMF TGGAAAAAGGCCGCATGAT 
YWHAZ  TMR TCTGTGGGATGCAAGCAAAG 
YWHAZ  TMP TGGCTCCACTCAGTGTCTAAGGCACCCT 
GAPDH RTF CAATGACCCCTTCATTGACCTC 
GAPDH  RTR CTCGCTCCTGGAAGATGGTGAT 
GAPDH  TMF GATTCCACCCATGGCAAATTC 
GAPDH  TMR GGGATTTCCATTGATGACAAGC 
GAPDH  TMP CGTTCTCAGCCTTGACGGTGCCA 
 



















Supplemental Table 3 
 
 
Antigen Fluorophore Concentration Clone 
CD14/16/19/20/56 
(lineage) 
FITC 1:100 total CD14 Biolegend 325603 
CD16 Biolegend 302005 
CD19 Biolegend 302205 
CD20 Biolegend 302203 





1:100  ebioscience 48-9459-42  
FcERI PE-Cy7 1:100 Biolegend 334620 
 
CD3 V500 1:100 BD 561416 
 
ckit BV711 1:100 Biolegend 313229 
 
CD123 APC-e780 1:100 ebioscience 47-1239-41 
 
Siglec A647 (APC) 1:640   Allakos 
ST2 biotin 1:100 mdbioproducts 101200B 
 
Antibody Fluorophore Concentration Clone 
CD3 FITC 1:100 UCHT1 
CD45RO eFluor450 1:100 Same Ab 
CD2 PE-Cy7 1:100 TS1/8 
CD3 V500 1:100 Same Ab 
CD25 BV711 1:100 104D2 
CD25 PE 1:100 N/A 
CD3 A647 (APC) 1:100 UCHT1 
CD4 eV605 1:100 SK3 
CD45 APC-Cy7 1:100 HI30 
